Sinovac Biotech, Ltd (SVA) Beats Q2 Estimates; Swings to Profit
Tweet
Share
E-mailGet Alerts SVA Hot Sheet
Join SI Premium – FREE
Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q2 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $15.7 million versus the consensus estimate of $5.66 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
